$IPX

IperionX received a $18.5M task order from the U.S. Army, with $11.5M funded, under an IDIQ contract for domestic titanium production. The order includes options up to $25.4M and covers equipment expansion and in-house finishing. The contract supports titanium parts for defense applications, aligning with IperionX's GenX platform.

IperionX Limited's options are under a 61-day lock-up agreement ending on 6-SEP-2026. Officers, directors, and certain securityholders agreed not to trade these options during this period. IperionX is a titanium and critical materials company with projects in the U.S. The company focuses on low-energy, low-carbon titanium production for various industries.

Jefferies initiated coverage of companies in advanced materials and energy-efficiency, citing demand from electrification, AI, and defense. Top picks include Element Solutions and Almonty Industries. The firm predicts supply bottlenecks in critical minerals, estimating $65-250 trillion in energy investment needs. Jefferies recommends focusing on companies with improving returns and margins, which have historically yielded 15% annual returns.

IperionX received $11.5M (up to $25.4M) from the U.S. Army for titanium powder and fastener production, part of a $99M SBIR Phase III program. The company aims to scale its titanium manufacturing platform and produce fasteners in-house in Virginia. IperionX also explores recycling and producing niobium powders, including the rare C103 alloy.

IperionX (IPX) secured a $19.8M U.S. Army contract for domestic titanium, with $79.2M remaining under the $99M IDIQ contract. The funding supports expanding titanium powder-to-part manufacturing capacity for defense applications, aiming to lower costs and shorten lead times. The program will increase production of titanium components like track pins and fasteners for the Army.

IperionX's shares rose after securing a $18.5 million contract with the US Army, with a potential value exceeding $25 million. The company's shares had previously declined 4% on August 30. IperionX is listed on the Australian Securities Exchange.

IperionX Ltd (ASX: IPX) secured a US$11.5 million contract from the U.S. Army, with a potential value of US$25.4 million, to scale up titanium production. The funding supports in-house manufacturing and equipment for defense applications, with possible expansions into aerospace and other markets. The company aims to boost production capacity and lower costs at its Virginia facility.

IperionX (NASDAQ:IPX) said April-May production fell while it updated HAMR furnace controls and tested powder types, then returned to prior levels by July. The company plans to increase furnace cycles to reach 200 metric tons per annum by year-end, expand downstream processing, and add new sintering furnaces. It also reported a Titan mineral sands feasibility study with >$800M after-tax NPV and 40% post-tax IRR.

Australian shares rose for a fourth session, with the S&P/ASX 200 up 0.68% to 9,208.10, led by miners (BHP, Fortescue, Rio Tinto, Mineral Resources). Oil stocks were weaker (Woodside, Origin Energy, Santos, Beach Energy). Tech gains included Block, WiseTech Global, Zip, Xero and Appen. Neuren Pharmaceuticals jumped after Q2 results and FY2026 guidance upgrade.

IperionX Limited (NASDAQ: IPX) said it plans to redomicile its ultimate parent to Texas, subject to approvals, and expects the new U.S. parent’s common stock to list directly on Nasdaq, replacing its ADS structure. The company also appointed Michael J. Loparco as an independent non-executive director effective Aug. 3, 2026.